Optimi Health Corp. (CSE: OPTI, NASDAQ: OPTH) announced on September 23, 2026, that it has completed and quality-released a production batch of 5mg naturally derived psilocybin capsules manufactured at its cGMP facility in Princeton, British Columbia. The single batch will serve a dual purpose: supplying a Health Canada-approved Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD), and fulfilling commercial orders for licensed clinics in Australia. Investors may be watching this milestone as evidence of Optimi's capacity to simultaneously advance clinical programmes and generate commercial revenue from the same licensed manufacturing operation.

Key Points

  • Optimi Health Corp. (CSE: OPTI / NASDAQ: OPTH / FSE: 8BN) is a commercial-stage pharmaceutical manufacturer based in Vancouver, British Columbia
  • A single cGMP batch of 5mg psilocybin capsules, manufactured under a Health Canada Drug Establishment Licence in Princeton, BC, has been completed and quality-released
  • The Phase 2 MDD trial is a multisite, open-label study of up to 200 participants; patient dosing is expected to be completed by end of 2027
  • Investors may watch for trial enrolment progress and any expansion of Australian clinic supply agreements

Single Princeton Facility Batch Serves Both Clinical Trial and Australian Clinics

The completed batch was manufactured end-to-end at Optimi's Princeton, British Columbia facility under its Health Canada Drug Establishment Licence, covering production, encapsulation, and release testing within one licensed site. The release states that this integrated manufacturing model means the clinical trial product and the commercial product share an identical formulation from the same batch. CEO Dane Stevens noted in the announcement that the Chemistry, Manufacturing and Controls file supporting future registration is already held by the company, which the disclosure suggests could reduce regulatory friction as clinical data accumulates.

Health Canada-Approved Phase 2 Trial Targets Major Depressive Disorder

The Phase 2 study is a multisite, open-label trial enrolling up to 200 participants, each receiving a single supervised dose of Optimi's 5mg psilocybin capsule. Patient dosing is expected to be completed by the end of 2027, according to the announcement. The release states that trial data are intended to assess safety and efficacy of psychedelic-assisted therapy, with the goal of building an evidentiary base to support potential registration in Canada and other jurisdictions. Optimi noted that none of its psilocybin products have received market authorisation from Health Canada.

Australian Treatment-Resistant Depression Market Provides Existing Commercial Revenue Stream

Optimi has supplied 5mg psilocybin capsules commercially to licensed Australian clinics since 2025, where the product is prescribed for treatment-resistant depression under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The release states that reimbursement is available from payers including the Department of Veterans' Affairs, the National Disability Insurance Scheme, WorkCover, and Medibank. The announcement also notes that more than 750 clinicians have completed relevant psychedelic-assisted therapy certification, and Optimi states it is not aware of any reported serious adverse events since commercial supply began.